KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Alnylam Pharmaceuticals posted quarterly Receivables - Other of $500.0 million for Q2 2021, little changed on a QoQ basis from $500.0 million in Q1 2021.

Alnylam Pharmaceuticals (ALNY) has 3 years of Receivables - Other data on file, last reported at $500.0 million in Q2 2021.

  • For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million; the trailing twelve-month figure through Jun 2021 stood at $500.0 million (changed N/A YoY), and the FY2020 full-year result was $500.0 million, changed N/A from the prior year.
  • Receivables - Other for Q2 2021 stood at $500.0 million, roughly flat from $500.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $500.0 million in Q3 2020 and bottomed at $12.5 million in Q4 2018.
  • The 3-year median for Receivables - Other is $500.0 million (2020), against an average of $402.5 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 500.00 Mn
Jun 30, 2021 500.00 Mn
Mar 31, 2021 500.00 Mn
Mar 31, 2021 500.00 Mn
Dec 31, 2020 500.00 Mn
Dec 31, 2020 500.00 Mn
Sep 30, 2020 500.00 Mn
Sep 30, 2020 500.00 Mn
Dec 31, 2018 12.50 Mn
Dec 31, 2018 12.50 Mn